首页 › 基金 › Tri Locum Partners LP › ELVN
Tri Locum Partners LP 对 ELVN 的持仓历史
ENLIVEN THERAPEUTICS INC · 医疗保健
Tri Locum Partners LP 在 Q3 2026 的 13F 申报中披露持有 ELVN(ENLIVEN THERAPEUTICS INC)410,236 股,市值约 US$18.8M,约占其申报组合的 3.72%,在其申报持仓中市值排名第 11 位。 Tri Locum Partners LP 最近 2 个申报季度中有 2 个季度披露了 ELVN 持仓,最早可追溯至 Q2 2026。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
Tri Locum Partners LP 对 ELVN 的持仓演变
Tri Locum Partners LP 于 Q2 2026 首次披露 ELVN 持仓:866,716 股(约 US$44.0M)。 在 2 次申报中,Tri Locum Partners LP 0 次增持、1 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 410,236 股、市值约 US$18.8M,环比减持 -456,480 股。。 持仓曾出现大幅变动:Q3 2026 减持约 53% (随后一个季度股价上涨 6%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2026 | 866.72K | $43.99M | 新进 |
| Q3 2026 | 410.24K | $18.81M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ELVN 与 13F 数据
ELVN(ENLIVEN THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 61 只申报持有 ELVN,申报仓位最大的包括:ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$294.5M), Vestal Point Capital, LP (US$203.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ELVN 的基金
- ORBIMED ADVISORS LLC 6.78M 股 · $343.91M · Q2 2026
- Polar Capital Holdings Plc 6.43M 股 · $294.53M · Q3 2026
- Vestal Point Capital, LP 4.00M 股 · $203.00M · Q2 2026
- Commodore Capital LP 3.27M 股 · $166.21M · Q2 2026
- Fairmount Funds Management LLC 1.86M 股 · $94.17M · Q2 2026
- Bellevue Group AG 1.49M 股 · $75.62M · Q2 2026
- First Light Asset Management, LLC 1.36M 股 · $69.06M · Q2 2026
- Siren, L.L.C. 1.48M 股 · $67.62M · Q3 2026
- Novo Holdings A/S 1.00M 股 · $50.75M · Q2 2026
- Logos Global Management LP 1.08M 股 · $49.51M · Q3 2026
- BAKER BROS. ADVISORS LP 905.19K 股 · $45.94M · Q2 2026
- First Turn Management, LLC 958.70K 股 · $43.95M · Q3 2026
更多关于 Tri Locum Partners LP
常见问题
How long has Tri Locum Partners LP held ELVN?
Tri Locum Partners LP has disclosed ELVN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Tri Locum Partners LP's current position in ELVN?
As of Q3 2026, Tri Locum Partners LP holds 410.24K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $18.81M, representing 3.72% of its reported portfolio and ranking #11.
Has Tri Locum Partners LP been buying or selling ELVN?
In the latest 13F filing (Q3 2026), Tri Locum Partners LP reduced its position in ELVN.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 61 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.